Neoprobe to Present at Rodman & Renshaw Annual Global Investment Conference
September 08 2011 - 11:00AM
Business Wire
Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer
of innovative oncology surgical and diagnostic products, today
announced that Dr. Mark Pykett, Neoprobe’s President and Chief
Executive Officer, will deliver a presentation to institutional
investors at 3:15 PM ET, Monday, September 12, 2011 at the Rodman
& Renshaw Annual Global Investment Conference, taking place at
The Waldorf-Astoria, New York.
Investors and the public are invited to listen to a live webcast
of Dr. Pykett’s presentation at
http://www.wsw.com/webcast/rrshq20/neop. An archived edition of the
presentation will be available for 30 days following the
presentation.
About Neoprobe
Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company
focused on enhancing oncology patient care and improving patient
benefit through radiopharmaceutical product development. Neoprobe
is actively developing two radiopharmaceutical agent platforms –
Lymphoseek® and RIGScanTM CR – to help surgeons better identify and
treat certain types of cancer. Neoprobe’s subsidiary, Cira
Biosciences, Inc., is also advancing a patient-specific cellular
therapy technology platform called ACT. Neoprobe’s strategy is to
deliver superior growth and shareholder return by bringing to
market novel radiopharmaceutical agents and advancing the Company’s
pipeline program through continued investment and selective
acquisitions. For more information, please visit
www.neoprobe.com.
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
From Oct 2023 to Oct 2024